LncRNA

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

1. LncRNA DLX6-AS1 as a potential molecular biomarker in the clinicopathology and prognosis of various cancers: a meta-analysis.Bioscience reports · 2020
   Pooled it
2. Long Non-coding RNAs in Non-small Cell Lung Carcinoma: Regulatory Mechanisms, Diagnostic Potential, and Therapeutic Perspectives.Current drug targets · 2026
   Review
3. Cancer Biology of GSPT1: Mechanisms and Targeted Therapy Opportunities of Molecular Glue Degraders.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
   Review
4. Identification of prognostic biomarkers of sepsis and construction of ceRNA regulatory networks.Scientific reports · 2025
   Article
5. Exploration of patient plasma exosomes as biomarkers for predicting lung cancer brain metastasis.Frontiers in medicine · 2025
   Article
6. Prognostic biomarkers based onTranslational cancer research · 2024
   Article
7. Comprehensive landscape and future perspective of long noncoding RNAs in non-small cell lung cancer: it takes a village.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
   Review
8. Crosstalk between long noncoding RNA and microRNA in Cancer.Cellular oncology (Dordrecht, Netherlands) · 2023
   Review
9. LncRNA FAM138B inhibits the progression of non-small cell lung cancer through miR-105-5p.Cell cycle (Georgetown, Tex.) · 2023
   Article
10. GSPT1 Functions as a Tumor Promoter in Human Liver Cancer.Current medical science · 2023
    Article
11. Research progress regarding long-chain non-coding RNA in lung cancer: a narrative review.Journal of thoracic disease · 2022
    Review
12. Overexpression of eRF3a Promotes Cell Proliferation and Migration in Liver Cancer.Current medical science · 2022
    Article
13. Strategies of LncRNA DLX6-AS1 on Study and Therapeutics.Frontiers in genetics · 2022
    Review
14. DLX6-AS1: A Long Non-coding RNA With Oncogenic Features.Frontiers in cell and developmental biology · 2022
    Review
15. Research progress of DLX6-AS1 in human cancers.Human cell · 2021
    Review
16. Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation.BMC pulmonary medicine · 2021
    Article
17. Liquid Biopsy in Cervical Cancer: Hopes and Pitfalls.Cancers · 2021
    Review
18. The underlying molecular mechanisms and prognostic factors of RNA binding protein in colorectal cancer: a study based on multiple online databases.Cancer cell international · 2021
    Article
19. Sevoflurane inhibits cell proliferation and migration of glioma by targeting the miR‑27b/VEGF axis.Molecular medicine reports · 2021
    Article
20. Identification of GSPT1 as prognostic biomarker and promoter of malignant colon cancer cell phenotypes via the GSK-3β/CyclinD1 pathway.Aging · 2021
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as